Reduced quality of life and greater psychological distress in vasovagal syncope patients compared to healthy individuals
- 28 November 2018
- journal article
- research article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (2), 180-188
- https://doi.org/10.1111/pace.13559
Abstract
Background Vasovagal syncope (VVS) patients have a reduced health‐related quality of life (HRQoL). There are limited data comparing HRQoL and psychological profile in VVS patients and healthy individuals. We tested the hypothesis that VVS patients have greater impairment in both HRQoL and psychological profile compared to healthy non‐fainting individuals, and that both outcome measures are negatively correlated for VVS patients. Methods The RAND 36‐Item Health Survey (RAND36), global health visual analogue scale (VAS), Hospital Anxiety and Depression Scale, Anxiety Sensitivity Index, and Positive and Negative Affect Schedule – Expanded Form were completed by healthy individuals and at baseline by VVS patients enrolled in the Second Prevention of Syncope Trial, a randomized, placebo‐controlled trial of fludrocortisone for VVS. Results Data were available on 76 VVS patients (34±14 years; 68% F) and 85 healthy participants (35±11 years; 80% F). Compared to healthy participants, VVS patients reported poorer HRQoL on all scales of the RAND36 and the VAS. VVS patients had significantly greater anxiety, depression, and anxiety sensitivity (each p < 0.001). VVS patients had more negative affect (p < 0.001) and less positive affect (p = 0.003) compared to healthy participants. Anxiety, depression, and anxiety sensitivity were negatively correlated with HRQoL for VVS patients, but not for healthy participants. Conclusion In this first direct comparison, VVS patients have a significantly reduced HRQoL and more anxiety and depression compared to healthy non‐fainting individuals. For VVS patients, there is a relationship between psychological distress and HRQoL, suggesting a potential benefit from more comprehensive assessment and treatment. This article is protected by copyright. All rights reservedKeywords
Funding Information
- National Center for Advancing Translational Sciences (UL1 TR000445)
- Canadian Institutes of Health Research (MOP142426)
This publication has 26 references indexed in Scilit:
- Association between psychological complaints and recurrence of vasovagal syncopeClinical Autonomic Research, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncopeEP Europace, 2006
- The Second Prevention of Syncope Trial (POST II)—a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: Rationale and study designAmerican Heart Journal, 2006
- Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled studyEP Europace, 2006
- Psychiatric profile, quality of life and risk of syncopal recurrence in patients with tilt-induced vasovagal syncopeEP Europace, 2005
- The rand 36‐item health survey 1.0Health Economics, 1993
- Anxiety sensitivity, anxiety frequency and the prediction of fearfulnessBehaviour Research and Therapy, 1986
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983